NCT06420154View on ClinicalTrials.gov

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

May 27, 2027

Study Completion Date

May 27, 2027

Conditions
Systemic Lupus Erythematosus (SLE)Sjogren's SyndromeSystemic SclerosisInflammatory MyopathyANCA Associated VasculitisAntiphospholipid Syndrome
Interventions
BIOLOGICAL

anti-CD19-CAR-T cells

"The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion"

Trial Locations (1)

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
collaborator

Shanghai First Song Therapeutics Co., Ltd

INDUSTRY

lead

First Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06420154 - The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter